Kintegral Advisory LLC Sells 1,814 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kintegral Advisory LLC trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 32.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,696 shares of the company's stock after selling 1,814 shares during the period. Kintegral Advisory LLC's holdings in IDEXX Laboratories were worth $1,552,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in IDXX. Smartleaf Asset Management LLC lifted its position in shares of IDEXX Laboratories by 10.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 635 shares of the company's stock valued at $262,000 after buying an additional 58 shares during the last quarter. SRS Capital Advisors Inc. raised its stake in shares of IDEXX Laboratories by 363.3% during the 4th quarter. SRS Capital Advisors Inc. now owns 366 shares of the company's stock worth $151,000 after acquiring an additional 287 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in IDEXX Laboratories during the fourth quarter valued at approximately $97,000. Schechter Investment Advisors LLC lifted its position in IDEXX Laboratories by 8.5% during the fourth quarter. Schechter Investment Advisors LLC now owns 496 shares of the company's stock valued at $205,000 after acquiring an additional 39 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in IDEXX Laboratories by 9.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,436 shares of the company's stock valued at $1,007,000 after acquiring an additional 218 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director directly owned 1,801 shares of the company's stock, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $546.31 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The firm has a fifty day moving average of $508.45 and a 200 day moving average of $453.73. The firm has a market cap of $43.93 billion, a PE ratio of 50.49, a PEG ratio of 3.96 and a beta of 1.54. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business's revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.71 earnings per share. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Stifel Nicolaus increased their price objective on IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a report on Wednesday. Morgan Stanley increased their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Jefferies Financial Group started coverage on IDEXX Laboratories in a research note on Tuesday. They set a "buy" rating and a $625.00 price target on the stock. Finally, Leerink Partners increased their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $558.11.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.